Association of renalase with clinical outcomes in hospitalized patients with COVID-19.
Renalase is a secreted flavoprotein with anti-inflammatory and pro-cell survival properties. COVID-19 is associated with disordered inflammation and apoptosis. We hypothesized that blood renalase levels would correspond to severe COVID-19 and survival. In this retrospective cohort study, clinicopath...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0264178 |
| _version_ | 1818315214252146688 |
|---|---|
| author | Basmah Safdar Melinda Wang Xiaojia Guo Charles Cha Hyung J Chun Yanhong Deng James Dziura Joe M El-Khoury Fred Gorelick Albert I Ko Alfred I Lee Robert Safirstein Michael Simonov Bin Zhou Gary V Desir |
| author_facet | Basmah Safdar Melinda Wang Xiaojia Guo Charles Cha Hyung J Chun Yanhong Deng James Dziura Joe M El-Khoury Fred Gorelick Albert I Ko Alfred I Lee Robert Safirstein Michael Simonov Bin Zhou Gary V Desir |
| author_sort | Basmah Safdar |
| collection | DOAJ |
| description | Renalase is a secreted flavoprotein with anti-inflammatory and pro-cell survival properties. COVID-19 is associated with disordered inflammation and apoptosis. We hypothesized that blood renalase levels would correspond to severe COVID-19 and survival. In this retrospective cohort study, clinicopathologic data and blood samples were collected from hospitalized COVID-19 subjects (March-June 2020) at a single institution tertiary hospital. Plasma renalase and cytokine levels were measured and clinical data abstracted from health records. Of 3,450 COVID-19 patients, 458 patients were enrolled. Patients were excluded if <18 years, or opted out of research. The primary composite outcome was intubation or death within 180 days. Secondary outcomes included mortality alone, intensive care unit admission, use of vasopressors, and CPR. Enrolled patients had mean age 64 years (SD±17), were 53% males, and 48% non-whites. Mean renalase levels was 14,108·4 ng/ml (SD±8,137 ng/ml). Compared to patients with high renalase, those with low renalase (< 8,922 ng/ml) were more likely to present with hypoxia, increased ICU admission (54% vs. 33%, p < 0.001), and cardiopulmonary resuscitation (10% vs. 4%, p = 0·023). In Cox proportional hazard model, every 1000 ng/ml increase in renalase decreased the risk of death or intubation by 5% (HR 0·95; 95% CI 0·91-0·98) and increased survival alone by 6% (HR 0·95; CI 0·90-0·98), after adjusting for socio-demographics, initial disease severity, comorbidities and inflammation. Patients with high renalase-low IL-6 levels had the best survival compared to other groups (p = 0·04). Renalase was independently associated with reduced intubation and mortality in hospitalized COVID-19 patients. Future studies should assess the pathophysiological relevance of renalase in COVID-19 disease. |
| first_indexed | 2024-12-13T09:01:58Z |
| format | Article |
| id | doaj.art-a111ebde11404e28bdb958cafdf68a52 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T09:01:58Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a111ebde11404e28bdb958cafdf68a522022-12-21T23:53:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01173e026417810.1371/journal.pone.0264178Association of renalase with clinical outcomes in hospitalized patients with COVID-19.Basmah SafdarMelinda WangXiaojia GuoCharles ChaHyung J ChunYanhong DengJames DziuraJoe M El-KhouryFred GorelickAlbert I KoAlfred I LeeRobert SafirsteinMichael SimonovBin ZhouGary V DesirRenalase is a secreted flavoprotein with anti-inflammatory and pro-cell survival properties. COVID-19 is associated with disordered inflammation and apoptosis. We hypothesized that blood renalase levels would correspond to severe COVID-19 and survival. In this retrospective cohort study, clinicopathologic data and blood samples were collected from hospitalized COVID-19 subjects (March-June 2020) at a single institution tertiary hospital. Plasma renalase and cytokine levels were measured and clinical data abstracted from health records. Of 3,450 COVID-19 patients, 458 patients were enrolled. Patients were excluded if <18 years, or opted out of research. The primary composite outcome was intubation or death within 180 days. Secondary outcomes included mortality alone, intensive care unit admission, use of vasopressors, and CPR. Enrolled patients had mean age 64 years (SD±17), were 53% males, and 48% non-whites. Mean renalase levels was 14,108·4 ng/ml (SD±8,137 ng/ml). Compared to patients with high renalase, those with low renalase (< 8,922 ng/ml) were more likely to present with hypoxia, increased ICU admission (54% vs. 33%, p < 0.001), and cardiopulmonary resuscitation (10% vs. 4%, p = 0·023). In Cox proportional hazard model, every 1000 ng/ml increase in renalase decreased the risk of death or intubation by 5% (HR 0·95; 95% CI 0·91-0·98) and increased survival alone by 6% (HR 0·95; CI 0·90-0·98), after adjusting for socio-demographics, initial disease severity, comorbidities and inflammation. Patients with high renalase-low IL-6 levels had the best survival compared to other groups (p = 0·04). Renalase was independently associated with reduced intubation and mortality in hospitalized COVID-19 patients. Future studies should assess the pathophysiological relevance of renalase in COVID-19 disease.https://doi.org/10.1371/journal.pone.0264178 |
| spellingShingle | Basmah Safdar Melinda Wang Xiaojia Guo Charles Cha Hyung J Chun Yanhong Deng James Dziura Joe M El-Khoury Fred Gorelick Albert I Ko Alfred I Lee Robert Safirstein Michael Simonov Bin Zhou Gary V Desir Association of renalase with clinical outcomes in hospitalized patients with COVID-19. PLoS ONE |
| title | Association of renalase with clinical outcomes in hospitalized patients with COVID-19. |
| title_full | Association of renalase with clinical outcomes in hospitalized patients with COVID-19. |
| title_fullStr | Association of renalase with clinical outcomes in hospitalized patients with COVID-19. |
| title_full_unstemmed | Association of renalase with clinical outcomes in hospitalized patients with COVID-19. |
| title_short | Association of renalase with clinical outcomes in hospitalized patients with COVID-19. |
| title_sort | association of renalase with clinical outcomes in hospitalized patients with covid 19 |
| url | https://doi.org/10.1371/journal.pone.0264178 |
| work_keys_str_mv | AT basmahsafdar associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT melindawang associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT xiaojiaguo associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT charlescha associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT hyungjchun associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT yanhongdeng associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT jamesdziura associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT joemelkhoury associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT fredgorelick associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT albertiko associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT alfredilee associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT robertsafirstein associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT michaelsimonov associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT binzhou associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 AT garyvdesir associationofrenalasewithclinicaloutcomesinhospitalizedpatientswithcovid19 |